SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates
SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p
How this was made
The 30-second read
Why it matters
The earnings release combines a sizable net loss with strong clinical and regulatory milestones, creating a nuanced price outlook.
Market read
The filing provides fresh data that could move ICU stock and informs biotech sector sentiment on rare‑disease device approvals.
What to watch
Cash balance of $4M and pending modular PMA submission could strain liquidity if additional funding is not secured.
SeaStar Medical Q3 2026: QUELIMMUNE net revenue of $635 thousand, up 247% year over year, while net loss widened to $(4,529) thousand
Net revenue rose 247% to $635 thousand from a small base, and the company states gross profit margins remained above 90%. Net loss widened to $(4,529) thousand from $(3,472) thousand, operating expenses rose 38% in the quarter (from $3,748 thousand to $5,168 thousand as printed), and cash fell to $3,989 thousand at September 30, 2026 from $11,980 thousand at December 31, 2025.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net revenue, Q3 2026GAAP | $635K | – | 247% |
| Cost of goods sold, Q3 2026GAAP | $48K | – | – |
| Gross profit, Q3 2026GAAP | $587K | – | – |
| Gross profit margin, Q3 2026 (as stated by the company)other | greater than 90% | – | – |
| Research and development expenses, Q3 2026GAAP | $3.57M | – | – |
| General and administrative expenses, Q3 2026GAAP | $1.59M | – | – |
| Total operating expenses, Q3 2026GAAP | $5.17M | – | – |
| Loss from operations, Q3 2026GAAP | −$4.58M | – | – |
| Interest income, Q3 2026GAAP | $54K | – | – |
| Interest expense, Q3 2026GAAP | −$2K | – | – |
| Total other income (expense), net, Q3 2026GAAP | $52K | – | – |
| Loss before provision for income taxes, Q3 2026GAAP | −$4.53M | – | – |
| Net loss, Q3 2026GAAP | −$4.53M | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(1.03) | – | – |
| Net revenue, nine months 2026GAAP | $1.75M | – | – |
| Cost of goods sold, nine months 2026GAAP | $148K | – | – |
| Gross profit, nine months 2026GAAP | $1.60M | – | – |
| Research and development expenses, nine months 2026GAAP | $8.44M | – | – |
| General and administrative expenses, nine months 2026GAAP | $5.13M | – | – |
| Total operating expenses, nine months 2026GAAP | $13.57M | – | – |
| Loss from operations, nine months 2026GAAP | −$11.97M | – | – |
| Interest income, nine months 2026GAAP | $214K | – | – |
| Interest expense, nine months 2026GAAP | −$16K | – | – |
| Other financing costs, nine months 2026GAAP | — | – | – |
| Total other income (expense), net, nine months 2026GAAP | $198K | – | – |
| Loss before provision for income taxes, nine months 2026GAAP | −$11.78M | – | – |
| Provision for income taxes, nine months 2026GAAP | $3K | – | – |
| Net loss, nine months 2026GAAP | −$11.78M | – | – |
| Net loss per share, basic and diluted, nine months 2026GAAP | $(2.85) | – | – |
| Net cash used in operating activities, nine months 2026GAAP | −$9.13M | – | – |
| Net cash provided by financing activities, nine months 2026GAAP | $1.14M | – | – |
Capital returns
- The filing reports no dividends and no share repurchases.
- Nine months 2026 proceeds from issuance of shares were $1,678 thousand, against $14,337 thousand in the nine months 2025 (as printed in the cash flow statement).
- Nine months 2026 proceeds from exercise of warrants and from pre-funded warrants are printed as nil; the 2025 comparatives were $1,818 thousand and $5,886 thousand.
- The company states it received $3.3 million of gross proceeds from warrant exercises in October 2026, which are not included in the September 30, 2026 cash balance.
- Payment of notes payable was $(541) thousand in the nine months 2026, against $(592) thousand in the nine months 2025.
What drove it
- The company states that net revenue increased to reflect increased sales of QUELIMMUNE.
- The company states that the increase in research and development expenses was primarily driven by increased clinical research activities for the NEUTRALIZE-AKI pivotal clinical trial, SCD development costs, personnel, and payroll costs.
- The company states that the decrease in general and administrative expenses was the result of a decline in personnel, legal, audit, and SEC-related costs, partially offset by increased professional services, director fees, and franchise taxes.
- The company states that the QUELIMMUNE therapy group showed statistically significant higher survival at Day 60, Day 90, and hospital discharge versus comparator cohorts in a 50-patient SAVE Registry analysis presented at ASN Kidney Week 2026.
- The company states that FDA's fulfilment of the SAVE Registry post-approval requirements now enables hospitals to use QUELIMMUNE without the research infrastructure the registry demanded, which may increase availability for these patients.
- The company states that CMS ICD-10-PCS codes, effective October 1, 2026, enable administrative, billing, and statistical reporting for use of the SCD therapy in patients with AKI requiring RRT in the inpatient hospital setting.
Concerns
- Net loss widened to $(4,529) thousand in Q3 2026 from $(3,472) thousand in Q3 2025, and the loss from operations widened to $(4,581) thousand from $(3,579) thousand.
- Cash fell to $3,989 thousand at September 30, 2026 from $11,980 thousand at December 31, 2025. The company states that the $3.3 million of October 2026 warrant proceeds are excluded from this balance.
- Stockholders' equity fell to $469 thousand at September 30, 2026 from $10,416 thousand at December 31, 2025.
- Net revenue of $635 thousand remains small relative to Q3 2026 research and development expenses of $3,574 thousand and total operating expenses of $5,168 thousand.
- The company's forward-looking statements list the risk that it may not be able to raise sufficient capital to fund its operations, including current or future clinical trials, and the risk that it may not be able to secure additional financing on acceptable terms.
- The company's forward-looking statements list the risk that it may never achieve or sustain profitability.
What to watch
- NEUTRALIZE-AKI enrollment: the company reports 251 of 339 patients enrolled and expects enrollment to complete by mid-year 2027.
- Regulatory timing: the company has submitted the first module of the modular PMA application for adult AKI in the ICU receiving CRRT, and states that priority review would apply once the final module with pivotal trial results is submitted, provided a positive outcome.
- Cash runway: cash at September 30, 2026 was $3,989 thousand, and the company states $3.3 million of gross warrant exercise proceeds were received in October 2026.
- QUELIMMUNE revenue trajectory: the company states that gross profit margins remained above 90%, and nine months 2026 net revenue was $1,745 thousand.
- Adoption following the SAVE Registry requirement fulfilment and the October 1, 2026 ICD-10-PCS coding effective date.
Balance sheet and cash flow
- Cash was $3,989 thousand at September 30, 2026, against $11,980 thousand at December 31, 2025. The company states cash of $4.0 million at September 30, 2026.
- Total assets were $5,310 thousand at September 30, 2026, against $14,158 thousand at December 31, 2025.
- Total liabilities were $4,841 thousand at September 30, 2026, against $3,742 thousand at December 31, 2025.
- Total stockholders' equity was $469 thousand at September 30, 2026, against $10,416 thousand at December 31, 2025.
- Accumulated deficit was $(163,494) thousand at September 30, 2026, against $(151,714) thousand at December 31, 2025.
- Accounts payable were $1,467 thousand and accrued expenses were $3,373 thousand at September 30, 2026, against $948 thousand and $2,268 thousand at December 31, 2025. Notes payable were nil at September 30, 2026, against $525 thousand at December 31, 2025.
- Net cash used in operating activities was $(9,128) thousand for the nine months 2026, against $(9,505) thousand for the nine months 2025.
- Stock-based compensation was $155 thousand for the nine months 2026, against $554 thousand for the nine months 2025.
Analysis
SeaStar Medical reported third quarter 2026 net revenue of $635 thousand, against $183 thousand in the third quarter of 2025, a 247% increase that the company attributes to increased sales of QUELIMMUNE. Cost of goods sold was $48 thousand, giving gross profit of $587 thousand against $169 thousand a year earlier. The company states that gross profit margins remained greater than 90%. Nine months 2026 net revenue was $1,745 thousand against $814 thousand, so the growth trend holds across both periods, although the revenue base remains very small against the company's cost structure.
Operating expenses rose from $3,748 thousand to $5,168 thousand. Research and development increased to $3,574 thousand from $1,850 thousand, and the company states this was primarily driven by clinical research for the NEUTRALIZE-AKI pivotal trial, SCD development costs, personnel, and payroll costs. General and administrative expenses fell to $1,594 thousand from $1,898 thousand, which the company attributes to lower personnel, legal, audit, and SEC-related costs, partly offset by professional services, director fees, and franchise taxes. Loss from operations widened to $(4,581) thousand from $(3,579) thousand, and net loss widened to $(4,529) thousand, or $(1.03) per share on 4.4 million weighted-average shares, from $(3,472) thousand, or $(1.30) per share, a year earlier. The per-share comparison is affected by the change in weighted-average share count, which the filing prints in full.
The balance sheet shows the funding position. Cash was $3,989 thousand at September 30, 2026, compared with $11,980 thousand at December 31, 2025. Nine months operating cash outflow was $(9,128) thousand, and financing inflow was $1,137 thousand, of which share issuance proceeds were $1,678 thousand against $14,337 thousand in the prior-year nine months. Total stockholders' equity was $469 thousand against $10,416 thousand at year end 2025. The company reports $3.3 million of gross warrant exercise proceeds received in October 2026, which it excludes from the September 30 cash figure. The filing does not contain financial guidance, so there is no reported outlook to compare against.
On the clinical and regulatory side, the company reports 251 of 339 patients enrolled in NEUTRALIZE-AKI, with enrollment expected to complete by mid-year 2027. It has submitted the first module of a modular PMA application, received a seventh Breakthrough Device Designation, fulfilled FDA post-approval requirements for the SAVE Registry study, and received ICD-10-PCS codes effective October 1, 2026. The SAVE Registry results presented at ASN Kidney Week are described by the company as statistically significant for higher survival in QUELIMMUNE-treated patients, based on 50 patients. The read-through for the reader is that commercial revenue is growing from a very small base, the pipeline milestones are progressing on the company's stated timelines, and the balance sheet is thin relative to a quarterly net loss of $(4,529) thousand.
Management, verbatim
The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications.
Eric Schlorff, CEO, SeaStar Medical
The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval.
Eric Schlorff, CEO, SeaStar Medical
Not in the filing
stated, not guessed- No financial guidance for Q4 2026 or FY 2026 is included in the filing; guidance is set to null.
- No previous-release outlook was provided, so vs_prior_guidance is empty.
- No prior-quarter (Q2 2026) figures are printed, so all prior_quarter and qoq_change fields are null.
- Year-over-year percentage changes are not printed for most lines except net revenue (247%); those fields are null.
- No segment or product-line revenue breakdown is printed beyond total net revenue.
- Gross margin as a percentage is not printed as a figure; the filing states only that gross profit margins remained greater than 90%, with no prior-period comparison.
- Cash flow statement lines for the three-month period are not printed; only nine-month cash flow figures are available.
- Nine-month 2026 and 2025 proceeds from warrant exercise and pre-funded warrant lines show nil and prior-year amounts without a current-year total for other financing items; no combined figure is computed.
- No dividend, buyback or debt facility information beyond the notes payable repayment line is printed.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SeaStar Medical (Nasdaq: ICU) filed a Form 8‑K reporting its Q3 2026 financials and key business updates, including a 247% revenue jump, trial enrollment progress, and a new FDA Breakthrough Device Designation.
Ticker impact
Q3 2026 results show net loss of $4.5M, 247% revenue increase, 75% trial enrollment and FDA Breakthrough Device Designation for its SCD therapy.
likely modest downside as loss dominates, but FDA breakthrough may limit sell‑off and support near‑term stability.
Losses and cash burn pressure the stock, yet the FDA designation and trial enrollment provide a catalyst for upside if investors focus on long‑term potential.
Market effects
Highlights growing interest in ultra‑rare pediatric AKI therapies and may boost peer biotech sentiment.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche medical device market.
Counterpoint
Despite the loss, the FDA breakthrough could trigger a short‑term rally as investors price in future approval potential.
Key entities
- companySeaStar Medical Holding Corp
Nasdaq‑listed developer of the QUELIMMUNE therapy for pediatric AKI.
- regulatorFDA
Granted Breakthrough Device Designation for SeaStar's SCD therapy.
